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Abstract 
Introduction: We describe the youngest case of enhanced S-cone syndrome (ESCS) associated 
with choroidal neovascularization (CNV) successfully treated with intravitreal ranibizumab in-
jections. Case Report: A 5-year-old boy presented with round-shaped fibrotic subretinal le-
sions in both eyes with surrounding subretinal fluid and progressive visual deterioration in the 
right eye. Fine foci of increased autofluorescence were observed along the arcades in both 
eyes. Fluorescein angiography revealed the presence of CNV in his right eye, and treatment 
with ranibizumab was initiated, with significant improvement in vision. Subsequent electro-
retinogram examination and genetic studies of the patient and his two younger siblings con-
firmed the diagnosis of ESCS. Conclusion: CNV has been reported to occur in different inher-
ited retinal degenerations, including ESCS. Our experience confirms that treatment with ranibi-
zumab in patients with CNV-complicated ESCS can be potentially vision-saving. 
 © 2018 The Author(s) 
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Introduction 
First described in 1990, enhanced S-cone syndrome (ESCS) is a rare, autosomal recessive 
retinal dystrophy associated with pathognomonic electrophysiological findings and NR2E3 
gene mutations. This gene encodes a transcription factor that regulates the proper differenti-
ation of photoreceptor cells. In fact, mutations in NR2E3 leading to loss of function of the tran-
scription factor are thought to be responsible for altering photoreceptor precursor cells fate 
from rod to S cone. This leads to a disorganized retina with lack of structurally recognizable 
rods and approximately twice the number of cones, most of which are S cones (short wave-
length), responsible for the detection of blue light. To date, at least 49 mutations in NR2E3 
have been described with resultant phenotypes of ESCS, Goldmann-Favre syndrome, and au-
tosomal dominant and autosomal recessive retinitis pigmentosa [1–3]. Characteristic features 
of electroretinograms in ESCS include undetectable rod-specific response, relatively increased 
responses to the shorter wavelengths of light, similar waveform response to a standard single 
flash under photopic and scotopic conditions, and profoundly delayed 30-Hz flicker ERG with 
lower amplitude than the single-flash light-adapted 3.0 ERG a-wave [4]. 
Choroidal neovascularization (CNV) has been reported to occur in a number of inherited 
retinal degenerations, including ESCS [5–7]. The prevalence of this latter association has not 
been estimated yet. Although uncommon, neovascularization can occur early in the course of 
the disease accelerating the loss of visual function. Published clinical reports of CNV-compli-
cated ESCS showed a relatively favorable visual prognosis with common tendency to a spon-
taneous involution of the low-active CNV to a small, circumscribed fibrotic subretinal scar. 
Being a rare clinical condition, there is still little information on the natural history and man-
agement of these lesions; however, few cases reported in the literature have shown that timely 
anti-VEGF treatment can prevent visual deterioration and leads to a better visual outcome in 
these patients [5, 8–10]. Here, we describe the efficacy of ranibizumab in the treatment of a 
case of CNV associated with ESCS. 
Clinical Case 
We present a case of a 5-year-old boy who came to our service in May 2011 due to eso-
tropia and vision loss in the right eye. He presented with a best corrected visual acuity (BCVA) 
of 20/80 in the right eye and 20/32 in the left eye. He had a cycloplegic hyperopic refractive 
error of 5.75 diopters in the right eye and 7.00 diopters in the left eye. Dilated fundus exami-
nation revealed a round-shaped pigmented subretinal lesion along the superior arcade with 
serous retinal epithelium detachment and retinal exudates in his right eye and a smaller 
round-shaped pigmented subretinal peripapillary lesion in his left eye. Pale white dots along 
the arcades were also observed in both eyes. Fluorescein angiography revealed the presence 
of CNV in the right eye and retinochoroidal anastomosis in the left eye. Optical coherence to-
mography showed an hyperreflective lesion with subretinal fluid and intraretinal cystic 
changes in the right eye and a peripapillary hyperreflective lesion in the left eye without exu-
dation. Fundus autofluorescence showed several fine foci of increased autofluorescence along 
the arcades in both eyes (Fig. 1). In June 2011, the patient received in his right eye two intra-
vitreal injections of ranibizumab over a 2-month period, and BCVA improved to 20/32 with 
complete disappearance of subretinal fluid, which remained stable over the years (Fig. 2). 
In the meantime, we decided to investigate his little sister and brother who were 3 and 1 
years old, respectively. Both of them presented with hyperopia and age-appropriate visual 
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acuity. Barely visible white dots were present along the arcades at fundus examination in both 
eyes of the two siblings, and autofluorescence imaging revealed the presence of multiple small 
hyperfluorescent foci along the arcades. 
Electroretinography of our patient displayed normal rod-specific ERG and normal oscil-
latory potentials. Dark-adapted maximal response and light-adapted cone response were nor-
mal and had a similar waveform. The 30-Hz flicker was delayed with very low amplitude. Full-
field ERG also showed a greatly magnified blue-cone signal. 
The standard full-field ERGs of his two siblings were very similar to each other and 
showed characteristic features. The rod-specific ERG was undetectable. The dark-adapted 
maximal response was reduced and had a similar waveform to the light-adapted cone re-
sponse, which had a normal amplitude. The 30-Hz flicker was severely reduced and delayed. 
We also observed an increased sensitivity to short wavelength light stimulus. 
The parents of the three children were also investigated. They both had a 20/20 visual 
acuity with normal fundus appearance and normal autofluorescence imaging. 
Genetic studies identified a homozygous splice site mutation, c.119–2A>C, in the NR2E3 
gene in all 3 affected siblings, confirming the diagnosis of ESCS. The parents and the paternal 
grandmother carried the variant heterozygously. 
After a 7-year follow-up, the patient’s BCVA is 20/20 in both eyes. In the right eye, the 
fibrotic lesion is stationary with adjacent intraretinal cysts and no signs of exudation, while in 
the left eye, a schisis-like maculopathy with intraretinal cystic changes has appeared (Fig. 3). 
His siblings also have a 20/20 BCVA with stationary fundus appearance in both eyes. 
Discussion 
CNV occurs in several retinal dystrophies. The association between CNV and ESCS is al-
ready well known [5–11], and very few of the previously reported cases have been treated 
with anti-VEGF [5, 8, 9]. To our knowledge, this is the youngest case of ESCS-associated CNV 
described in literature. 
The pathological pathway that promotes the evolution of CNV in ESCS patients has not 
been completely understood yet. There is evidence that retinal pigment epithelium (RPE) 
changes, photoreceptor dysfunction, and choriocapillaris damage, which are constantly pre-
sent in retinal dystrophies, may create weakness zones through which choroidal vessels can 
grow, leading to neovascularization. Furthermore, dysfunctional RPE may become hypoxic 
and produce VEGF that promotes angiogenesis [5, 10]. Other authors hypothesized that the 
increased number of cones in ESCS patients, which are known to have a higher oxygen de-
mand than rods, leads to an ischemic condition with upregulation of VEGF production and 
subsequent vascular abnormalities [8, 12]. 
CNV can trigger acute changes in central vision that are atypical in patients with heredi-
tary retinal dystrophies, and CNV-related visual loss can be the first clinical sign of ESCS. 
Therefore, any rapid decrease in visual acuity in these patients warrants urgent investigation 
for potential CNV [5, 10]. Young children rarely complain of vision loss, but indirect warning 
signs can be identified. Our patient did not suffer from night blindness or any other visual 
symptom except for acute onset esotropia in the affected eye secondary to visual loss due to 
subretinal fluid. 
Although CNV associated with inherited retinal dystrophies seems to have a relatively fa-
vorable visual prognosis, if left untreated, it can lead to persistent visual loss due to the devel-
opment of fibrotic subretinal scars [10, 13]. Furthermore, in young children, it can affect the 
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development of the visual system and lead to deprivation amblyopia. Despite the high possi-
bility of spontaneous regression of CNV in children, the mean visual acuity in eyes treated with 
anti-VEGF agents seems to be higher than in eyes with spontaneously regressed CNV. There-
fore, early diagnosis and treatment of this complication is of utmost importance [14]. The fi-
brotic subretinal peripapillary lesion associated with retinochoroidal anastomosis in the fel-
low eye of our patient might suggest that an early neovascular membrane had occurred and 
involuted. These findings could confirm that CNV associated with ESCS presents early in the 
course of the disease and regresses spontaneously, leading to a circumscribed subretinal scar 
[7, 9, 10]. 
Back in 2011, the efficacy of both bevacizumab and ranibizumab in treating pediatric CNV 
was reported. Moreover, no adverse effects were observed in clinical practice with pediatric 
use of both anti-VEGF agents [15]. Rishi et al. [14] reported that since ranibizumab has a 
shorter serum half-life than bevacizumab, it may lower systemic exposure in children. Nowa-
days, considering the increasing use of anti-VEGF agents in pediatric patients, long-term safety 
results need to be further evaluated. In our patient, treatment with ranibizumab led to a com-
plete resolution of subretinal fluid and a great improvement in visual acuity, which remained 
stationary after a 7-year follow-up. We did not observe any short-term ocular or systemic ad-
verse effects of treatment with intravitreal ranibizumab. 
It is important to note that intraretinal cysts in ESCS are mainly attributable to chronic 
degeneration and disorganization of the retina associated with loss of photoreceptos and RPE 
pump dysfunction rather than neovascularization. Cystic changes are considered a pathogno-
monic finding of the disease and should not be confused with a sign of neovascularization; 
fluorescein angiography can be a useful tool to distinguish between these two conditions [5, 
11]. 
Fundus hyperautofluorescent spots, typically observed in ESCS, seem to be generated by 
chromophores within the cytoplasm of macrophages, recruited into the retina to support the 
role of RPE in removing damaged photoreceptors and outer segment debris [7]. 
In conclusion, considering the previously reported clinical cases of anti-VEGF treatment 
for CNV in ESCS [5, 6, 8, 9], we described several novel features. First, in young children, the 
disease can present with atypical or indirect symptoms: our patient did not complain of night 
blindness, but he suffered from acute-onset esotropia as a consequence of vision impairment. 
Second, the number of ranibizumab injections needed to obtain a complete regression of the 
CNV was the lowest described in the literature, and our patient was the youngest child to be 
treated for this condition. Furthermore, to our knowledge, this is the longest follow-up of a 
patient successfully treated with ranibizumab for this disease. Our experience confirms that 
anti-VEGF therapy in ESCS patients can be potentially vision-saving and can prevent chronic 
visual deterioration secondary to CNV. 
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Fig. 1. Color fundus photography (a), fundus autofluorescence imaging (b), fluorescein angiography (c), 
and OCT images (d) of the patient in May 2011 (right eye in the upper line, left eye in the lower line). 
 
 
Fig. 2. Color fundus photography (a) and OCT images (b) of the patient in the right eye after two ranibi-
zumab injections. 
 
 
Fig. 3. Color fundus photography (a) and OCT images (b) of the patient in 2018 (right eye in the upper line, 
left eye in the lower line). 
 
